Table 3.
Correlation analysis between FBXL19 expression and clinical features of patients with HCC.
| Clinical features | Cases | FBXL19 |
p value | ||
|---|---|---|---|---|---|
| Low | High | ||||
| Gender | 0.129 | ||||
| Female | 12 | 6(50 %) | 6(50 %) | ||
| Male | 75 | 21(28 %) | 54(72 %) | ||
| Age(years) | 0.237 | ||||
| ≤50 | 42 | 10(23.81 %) | 32(76.19 %) | ||
| ＞50 | 45 | 17(37.78 %) | 28(62.22 %) | ||
| AFP(ng/mL) | 0.542 | ||||
| ≤200 | 59 | 23(38.98 %) | 36(61.02 %) | ||
| ＞200 | 28 | 9(32.14 %) | 19(67.86 %) | ||
| HBsAg | 0.462 | ||||
| Positive | 70 | 23(32.86 %) | 47(67.14 %) | ||
| Negative | 17 | 4(23.53 %) | 13(76.47 %) | ||
| Hepatocirrhosis | 0.239 | ||||
| Yes | 68 | 23(33.82 %) | 45(66.18 %) | ||
| No | 19 | 4(21.05 %) | 15(78.95 %) | ||
| Tumor size(cm) | <0.001 | ||||
| ≤5 | 35 | 12(34.29 %) | 23(65.71 %) | ||
| ＞5 | 52 | 15(28.85 %) | 37(71.15 %) | ||
| Differentiation | 0.04 | ||||
| Well to moderate | 61 | 23(37.70 %) | 38(62.30 %) | ||
| Low | 26 | 4(15.38 %) | 22(84.62 %) | ||
| TNM stage | 0.021 | ||||
| I-II | 63 | 24(38.10 %) | 39(61.90 %) | ||
| III-IV | 24 | 3(12.50 %) | 21(87.50 %) | ||
Footnotes: AFP, alpha fetoprotein; HBsAg, hepatitis B surface antigen; TNM, tumor node metastasis.